iPSC-CM suppresses the p38/JNK pathway. (A) Western blot (upper) and quantification (lower) of p38, JNK (B), Akt (C) and Erk (D) phosphorylation from the irradiation injury lacrimal gland showing the effects of administering MFCM, p38 inhibitor (SB203580, a p38 MAPK inhibitor with IC50 of 0.3–0.5 μM.) or iPSC-CM on p38 phosphorylation in irradiation injury lacrimal glands. Lacrimal injury was induced in mice receiving radiotherapy. Data shown are the mean ± SD of five independent experiments. In (A), (B) and (C) * p<0.05 vs. normal, normal + CM, RT + CM, or RT + SB203580; In (D) * p < 0.05 vs. normal + CM, RT, RT + CM, RT + MFCM, or RT + SB203580 (normal + CM: non-irradiated after iPSC-CM treatment, RT: radiotherapy, RT + CM: radiotherapy after iPSC-CM treatment, RT + MFCM: radiotherapy after mouse fibroblasts conditioned medium treatment); N = 5.